Health ❯ Healthcare ❯ Chronic Conditions

Obesity

Weight Management Treatment Options Type 2 Diabetes Health Risks Weight Loss Treatments Weight Loss Medications Cardiovascular Health Weight Regain Hypertension Treatment Strategies

3 ARTICLES

2w ago

GLP‑1 Agonists Linked to Lower Clot Risk and Mortality in People With Obesity and Autoimmune Disease

A large electronic health record target‑trial emulation found lower rates of stroke, pulmonary embolism, ED visits, and death but authors say randomized trials are needed to test causality.

6 ARTICLES

2w ago

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

3 ARTICLES

4mo ago

Heart Attack Alerts Shift Toward Younger Adults as German Experts Push Prevention

9 ARTICLES

4mo ago

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

9 ARTICLES

4mo ago

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

4 ARTICLES

5mo ago

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

5 ARTICLES

5mo ago

BMJ Review Finds Rapid Weight Regain After Stopping GLP-1 Weight-Loss Injections

9 ARTICLES

6mo ago

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

24 ARTICLES

7mo ago

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

3 ARTICLES

8mo ago

Hypertension in Mexico Is Hitting Younger Adults as Sonora Logs 2025 Increase

3 ARTICLES

9mo ago

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

5 ARTICLES

9mo ago

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

5 ARTICLES

10mo ago

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults

4 ARTICLES

11mo ago

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

Obesity

GLP‑1 Agonists Linked to Lower Clot Risk and Mortality in People With Obesity and Autoimmune Disease

UAE Becomes First Country Outside U.S. to Offer Wegovy Pill

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

New Data Tie GLP-1 Drugs’ Broad Benefits to Inflammation

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

FDA Orders Post-Approval Safety Studies for Lilly’s Foundayo Weight-Loss Pill

UK Regulators Approve Single-Dose 7.2mg Wegovy Pen for Weekly Use

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

Heart Attack Alerts Shift Toward Younger Adults as German Experts Push Prevention

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

Never miss stories about

Obesity

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

BMJ Review Finds Rapid Weight Regain After Stopping GLP-1 Weight-Loss Injections

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Hypertension in Mexico Is Hitting Younger Adults as Sonora Logs 2025 Increase

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

Never miss stories about

Obesity